Expression of Endothelial Cell Injury Marker Cd146 Correlates with Disease Severity and Predicts the Renal Outcomes in Patients with Diabetic Nephropathy

• Published in: Cellular physiology and biochemistry Vol. 48; no. 1; pp. 63 - 74
• Main Authors: Fan, Ying, Fei, Yang, Zheng, Li, Wang, Jiemin, Xiao, Wenzhen, Wen, Jiejun, Xu, Yanping, Wang, Yiyun, He, Li, Guan, Jian, Wei, Jia, He, John Cijiang, Wang, Niansong
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.01.2018; Cell Physiol Biochem Press GmbH & Co KG
• Subjects: Adult; Aged; Albuminuria; Angiogenesis; Area Under Curve; Biomarkers - blood; Biopsy; Case-Control Studies; Cd146; CD146 Antigen - blood; Chronic kidney disease; Creatinine - blood; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - diagnosis; Diabetic Nephropathies - complications; Diabetic Nephropathies - pathology; Diabetic nephropathy; Endothelial dysfunction; Female; Glomerular Filtration Rate; Humans; Immunohistochemistry; Injuries; Kidney - metabolism; Kidney - pathology; Kidney diseases; Laboratories; Male; Middle Aged; Original Paper; ROC Curve; Serum Albumin - analysis; Severity of Illness Index; Up-Regulation; Endothelial dysfunction; Diabetic nephropathy; Chronic kidney disease; Albuminuria; Cd146
• ISSN: 1015-8987; 1421-9778
• DOI: 10.1159/000491663

Background/Aims: Glomerular endothelial cell injury plays a crucial role in the development of diabetic nephropathy (DN). CD146, an endothelial marker, was shown to increase in chronic kidney disease (CKD), but its role in DN remains unknown. We aim to assess whether CD146 could be used to evaluate disease severity and predict renal outcomes in DN at early stages. Methods: 159 non-dialysis type 2-DN patients from 2008 to 2015 were enrolled to measure the plasma concentration of soluble CD146 (sCD146). 94 type 2 diabetes mellitus patients without DN and 100 healthy subjects were used as controls. The patients with CKD stage 1-3 were referred as early stage patients. Another independent cohort of 48 patients with biopsy-proved DN was used for the immunohistochemistry study of CD146. Renal outcomes were defined as doubling of serum creatinine, initiation of renal replacement therapy or death. Results: We found that plasma level of sCD146 was upregulated and associated with renal function in DN patients. sCD146 was proved to be a more optimal marker than urine albumin creatinine ratio to evaluate disease severity in these DN patients. The kidney expression of CD146 was co-localized with endothelial marker CD31 and increased in DN. CD146 staining in kidney was correlated with the severity of pathological changes in DN patients. Survival analysis suggested that both plasma and biopsy expression of CD146 were correlated with renal outcomes. Conclusions: CD146 is associated with kidney injury and could be a good marker to predict renal outcomes in patients with early stages of DN.